This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yao, E. S. Articles by Park, C. Search for Related Content PubMed PubMed Citation Articles by Yao, E. S. Articles by Park, C.

Increased ß₁ Integrin Is Associated with Decreased Survival in Invasive Breast Cancer

Departments of ¹ Radiation Oncology and ² Pathology, ³ Comprehensive Cancer Center and Department of Laboratory Medicine, and ⁴ Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California and ⁵ Lawrence Berkeley National Laboratory, Berkeley, California

Requests for reprints: Catherine Park, Department of Radiation Oncology, University of California at San Francisco/Mt. Zion Cancer Center, 1600 Divisadero Street H1031, San Francisco, CA 94143-1708. Phone: 415-353-7186; Fax: 415-353-9883; E-mail: Catherine.park{at}ucsf.edu.

Aberrant microenvironments and loss of balance in cell-extracellular matrix signaling are associated with breast cancer invasion, metastasis, and resistance to therapy. We have recently shown that increased ß₁ integrin signaling is involved in malignant progression and that inhibitory antibody to ß₁ integrin leads to selective apoptosis and decreased proliferation in three-dimensional cultures and in xenograft models of breast cancer in vivo. To investigate the clinical importance of these findings, in the present study we examined the expression of ß₁ integrin and extracellular ß₁ integrin ligands fibronectin and laminin-1 in a cohort of 249 breast cancer patients who had a median follow-up of 8.4 years. Among the 149 scorable cases, the highest ß₁ integrin intensity score (3+ versus 0–2+) was associated with significantly decreased 10-year overall survival of 48% versus 71% (P < 0.03) and decreased disease-free survival of 50% versus 80% (P < 0.05). Importantly, high fibronectin expression was associated with decreased overall and disease-free survival on univariate analysis (P < 0.04) and ß₁ integrin intensity score was significantly correlated with fibronectin expression (Kendall's tau-b = 0.19; P = 0.03). In a multivariate Cox proportional hazards model, ß₁ integrin intensity score remained a significant independent predictor of overall survival [hazard ratio (HR), 1.69; 95% confidence interval (95% CI), 1.19–2.38; P < 0.003] and disease-free survival (HR, 1.87; 95% CI, 1.21–2.88; P < 0.005). These findings show that ß₁ integrin expression has potential prognostic value in invasive breast cancer and that coexpression of fibronectin may help identify patients with more aggressive tumors who may benefit from targeted therapy. [Cancer Res 2007;67(2):659–64]

This article has been cited by other articles:

				H. L. Goel, J. Li, S. Kogan, and L. R Languino Integrins in prostate cancer progression Endocr. Relat. Cancer, September 1, 2008; 15(3): 657 - 664. [Abstract] [Full Text] [PDF]

				C. C. Park, H. J. Zhang, E. S. Yao, C. J. Park, and M. J. Bissell {beta}1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts Cancer Res., June 1, 2008; 68(11): 4398 - 4405. [Abstract] [Full Text] [PDF]

				C. M. Williams, A. J. Engler, R. D. Slone, L. L. Galante, and J. E. Schwarzbauer Fibronectin Expression Modulates Mammary Epithelial Cell Proliferation during Acinar Differentiation Cancer Res., May 1, 2008; 68(9): 3185 - 3192. [Abstract] [Full Text] [PDF]

				M. B. Meads, L. A. Hazlehurst, and W. S. Dalton The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance Clin. Cancer Res., May 1, 2008; 14(9): 2519 - 2526. [Abstract] [Full Text] [PDF]